Neo-adjuvant exemestane in elderly patients with breast cancer: A phase II, multicentre, open-label, Italian study

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 655-659

  Mustacchi, G ^a,e   Mansutti, M ^b   Sacco, C ^b   Barni, S ^c   Farris, A ^d   Cazzaniga, M ^c   Cozzi, M ^b   Dellach, C ^a  

^a Cattedra di Oncologia Medica Centro Oncologico   (Italy)

^b Dipartimento Interaziendale di Neurologia   (Italy)

^c Medical Oncology   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Aromatase inhibitor; Breast cancer; Endocrine therapy; Exemestane; Neo adjuvant

Indexed keywords

EXEMESTANE;

AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; ITALY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEGMENTAL MASTECTOMY;

EID: 63549102924     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn687     Document Type: Article

References (39)

1. Cazzaniga ME, Mustacchi G, Pronzato P et al. NORA Study Group. Adjuvant systemic treatment of early breast cancer: The NORA study. Ann Oncol 2006; 17: 1386-1392.
2. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003; 14: 414-420.
3. Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006; 33: 650-656.
4. Urruticoechea J, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
5. Mustacchi G, Latteier J, Milani S et al. Tamoxifen versus surgery plus tamoxifen as primary treatment for elderly patients with breast cancer: combined data from the "GRETA" and "CRC" trials. Proc Am Soc Clin Oncol 1998; 17: 99a (Abstr 383).
6. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
7. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
8. Cataliotti L, Buzdar A, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women in hormone-receptor positive breast cancer. Cancer 2006; 106: 2095-2103.
9. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicentre study. Ann Oncol 2001; 12: 1527-1532.
10. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004: 6 (Abstr 515).
11. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
12. Dixon JM, Grattage L, Renshaw L et al. Exemestane as Neoadjuvant treatment for locally advanced breast cancer: Endocrinologic and clinical endpoints. Breast Cancer Res Treat 2000; 62: 53 (Abstr 170).
13. Gil M, Barnadas A, Cirera L et al. Exemestane as neoadjuvant treatment in patients > 65 years with T > 3 cm; preliminary results of a multicenter Spanish Phase II trial. Breast Cancer Res Treat 2004; 76 (Suppl 1): S76 (Abstr 272).
14. Mlineritsch B, Tausch C, Singer C et al. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: A phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 2008; 112 (1): 203-213. Epub 2007 Dec 22.
15. Takei H, Suemasu K, Inoue K et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 2008; 107: 87-94.
16. Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane vs tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol 2005; 23: 16S (Abstr 530).
17. Bates T, Riley DL, Fallowfield L, Baum M. Breast cancer in elderly women: A cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991; 78: 591.
18. Mauriac L, Debled M, Durand M et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002; 13: 293-298.
19. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
20. Mustacchi G, Farris A, Barni S et al. Exemestane as primary treatment in hormonosensible early breast cancer of the elderly. Preliminary results of a phase II multicenter open Italian Study. Proc Am Soc Clin Oncol 2006: 18S (Abstr 10689).
21. Paepke S, Tulusan A, Kiesel L et al. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc Am Soc Clin Oncol 2003; 22: 80 (Abstr 321).
22. Renshaw L, Murray J, Young O et al. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 2004; 88 (Suppl 1): S36 (Abstr 405).
23. Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11 (2 Pt 2): 951s-958s.
24. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170.
25. Miller WR. Do classical oestrogen markers predict for clinical response to endocrine therapy? Breast Cancer Res 2007; 9 (Suppl 2): S19.
26. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
27. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
28. Paik S, Shak S, Tang G et al. Multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
29. Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffinembedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
30. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-1545.
31. Mauriac L, Durand M, Avril A et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991; 2: 347-354.
32. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
33. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
34. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
35. Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012-2017.
36. Petit T, Wilt M, Velten M et al. Is pathologic complete response related to level of hormonal receptor positivity in hormonal-sensitive breast cancer treated with anthracycline-based neo-adjuvant chemotherapy? Breast Cancer Res Treat 2007; 106 (Suppl 1): S174 (Abstr 4024).
37. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 15: 5678-5685.
38. Willsher PC, Robertson JFR, Chan SY et al. Locally advanced breast cancer: Early results of a randomised trial of multimodal versus initial hormone therapy. Eur J Cancer 1997; 33: 45-49.
39. Semiglazov VF, Semiglazov VV, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. Proc Am Soc Clin Oncol (Post-Meeting Edition) 2004; 22: 519.